Navigation Links
Delcath to Update Investors on FDA Meeting

NEW YORK, April 5, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), a development stage, specialty pharmaceutical and medical device company focused on oncology, announced today that the Company will meet this week with the U.S. Food & Drug Administration (FDA) to discuss the Refusal to File letter that it received from the FDA on February 18, 2011 and the resubmission of its New Drug Application (NDA) for its proprietary chemosaturation system.  Delcath management will host a conference call to provide an update to investors on the status of the resubmission of its NDA on April 11, 2011 at 4:30 p.m. Eastern Time.  

Conference Call InformationThe dial-in number for the conference call is 866-225-8754 for domestic participants and 480-629-9692 for international participants.  An audio replay of the call will be available for seven days following the call, and can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4431725#.  The call will also be available on the Internet live and for 7 days thereafter at

About Delcath SystemsDelcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology.  Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents.  The Company's initial focus is on the treatment of primary and metastatic liver cancers.  In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi–arm Phase II trial to treat other liver cancers.  The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system.  For more information, please visit the Company's website at

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward–looking statements made by the Company or on its behalf.  This news release contains forward–looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.  Factors that may cause such differences include, but are not limited to, uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales in the United States, acceptance of the Company's CE Mark Technical File by its Notified Body, receipt of CE Mark approval, adoption, use and resulting sales in the EU, if any, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, approval of the current or future chemosaturation system for other indications, actions by the FDA or other regulatory agencies, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities.  These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission.  You should not place undue reliance on these forward–looking statements, which speak only as of the date they are made.  We undertake no obligation to publicly update or revise these forward–looking statements to reflect events or circumstances after the date they are made.Investor Contact:

Media Contact:Gregory Gin/Doug Sherk

Janine McCargoEVC Group

EVC Group646-455-4801/415-896-6818


SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Expands Board of Directors With Appointment of Gabriel Leung
2. Delcath to Present at Upcoming Investor Conferences
3. Delcath Systems Receives Refusal to File Letter From FDA
4. Delcath Achieves ISO 13485 Certification
5. Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
6. Delcath Systems Announces Third Quarter Progress Report Conference Call
7. Delcath Strengthens Research and Development Team with Key Appointments
8. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
9. Delcath to Present at the William Blair Emerging Growth Stock Conference
10. Delcath to Present at the JMP Securities Healthcare Conference
11. Delcath Systems Announces Completion of Common Stock Offering
Post Your Comments:
(Date:11/26/2015)... Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische ... ) --> ...      (Photo: ) ... Universitair Medisch Centrum (LUMC) blijkt ...
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official ... independent group of Microsoft Dynamics SL software users, partners, industry experts and representatives. ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment ... itself for not only fulfilling the needs of advisers and clients but going ... price and providing top-tier customer service. However, there's always room for improvement, which ...
(Date:11/27/2015)... ... 27, 2015 , ... CBD College is proud to announce that ... awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join ... twelve colleges and universities in the state of California make the cut. CBD College ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Dr. ... Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., ... observed that both STEMI and Sepsis conditions present in similar ways and require time-critical ...
(Date:11/27/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class ... (Long Term Support) into its Q-Suite 5.10 product line. , Making the change ... version of Asterisk that will receive not only security fixes, but feature and ...
Breaking Medicine News(10 mins):